[O18] Oral Session 18　消化器3（下部消化管-大腸癌2）
【E】

[O18-4] Exploratory Biomarker Analysis of Trastuzumab Deruxtecan in HER2-Expressing Metastatic Colorectal Cancer (DESTINY-CRC01)

^○山口 研成¹, Siena Salvatore², Raghav Kanwal³, 舛石 俊樹⁴, 仁科 智裕⁵, Elez Elena⁶, Rodriguez Javier⁷, Chau Ian⁸, Di Bartolomeo Maria⁹, 川上 尚人¹⁰, 須藤 史貴¹¹, 小林 孝二郎¹¹, 古賀 牧土¹², 稲木 公一郎¹², 桑原 佑典¹², 竹原 一成¹², Grothey Axel¹³, 吉野 孝之¹⁴ (1.がん研究会有明病院, 2.Department of Oncology and Hemato-Oncology, Università degli Studi di Milano and Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy, 3.Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 4.愛知県がんセンター, 5.四国がんセンター, 6.Hospital Universitari Vall d’Hebron Institite of Oncology (VHIO), Barcelona, Spain, 7.Clinica Universidad de Navarra, Navarra, Spain, 8.Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, 9.Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, 10.近畿大学病院, 11.Daiichi Sankyo, Inc., Basking Ridge, NJ, USA, 12.第一三共株式会社, 13.West Cancer Center, Germantown, TN, USA, 14.国立がん研究センター東病院)